Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99940 | 0.87 | MAOA (0.52) | MAOAMAOBAPPEPHX2LMNA | |
| SCHEMBL21787518 | 0.82 | APP (0.41) | MAOAMAOBAPPEPHX2LMNA | |
| SCHEMBL918371 | 0.81 | APP (0.39) | MAOAMAOBAPPEPHX2 | |
| SCHEMBL918312 | 0.79 | APP (0.50) | APPEPHX2LMNASLC6A6CYP2C19 | |
| SCHEMBL12531321 | 0.79 | EPHX2 (0.40) | MAOAMAOBAPPEPHX2LMNA | |
| SCHEMBL15927240 | 0.79 | APP (0.39) | MAOAMAOBAPPEPHX2LMNA | |
| SCHEMBL17266136 | 0.78 | APP (0.44) | MAOAMAOBAPPEPHX2LMNA | |
| SCHEMBL20840057 | 0.78 | MAOA (0.61) | MAOAMAOBCYP2C19 | |
| SCHEMBL2121438 | 0.77 | APP (0.48) | APPEPHX2LMNASLC6A6CYP2C19 | |
| SCHEMBL30298818 | 0.76 | PAOX (0.39) | MAOAMAOBAPPEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246344-A1 | Biological buffers with wide buffering ranges | DALY THOMAS (US) | 2021-08-12 | — | — | US | disclosed |
| EP-3660111-A1 | INK COMPOSITION, METHOD FOR PRODUCING SAME, AND IMAGE FORMATION METHOD | FUJIFILM Corporation (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2020-03-05 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| EP-1836161-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | MAOA 528/4885MAOB 481/4885APP 1/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | MAOA 217/4885MAOB 208/4885APP 1/4885 |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | MAOA 385/4885MAOB 123/4885APP 2720/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | MAOA 165/4885MAOB 151/4885APP 1/4885 |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | PEF1, SLC7A1, PLPBP | MAOA 389/4885MAOB 122/4885APP 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.